Fulcrum Therapeutics Stock Price, News & Analysis

Fulcrum Therapeutics (NASDAQ: FULC) announced on February 11, 2022, the grant of inducement awards to Amy Winnen, the new Vice President, Head of Market Value, Access and Policy. The award includes a nonstatutory option to purchase 43,260 shares at an exercise price of $10.93, the closing price on February 7, 2022. Approved by independent directors, the option vests over four years and is part of Nasdaq Listing Rule compliance. Fulcrum focuses on developing treatments for genetically defined rare diseases, with lead programs targeting facioscapulohumeral muscular dystrophy and sickle cell disease.

Fulcrum Therapeutics, a clinical-stage biopharmaceutical company focusing on genetically defined rare diseases, announced participation in the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 9:20 a.m. ET. A live audio webcast will be available on their investor relations website, with an archived replay accessible for 30 days. Fulcrum's lead programs include losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 targeting sickle cell disease.

Fulcrum Therapeutics announced the first patient has been dosed in the Phase 1b trial of FTX-6058 for sickle cell disease, with initial data expected in 2Q 2022. An IND submission for FTX-6058 to support trials in select hemoglobinopathies is also planned for 2Q 2022. The company aims to provide updates on losmapimod in 1Q 2022. Kate Haviland has been appointed chair of the board of directors. Fulcrum reported a cash position of $218.2 million as of December 31, 2021, sufficient to fund operations into 2024.

Fulcrum Therapeutics (Nasdaq: FULC) announced the grant of an inducement award to newly appointed CFO Esther Rajavelu, approved by independent directors on January 3, 2022. The award includes a nonstatutory option to purchase 200,000 shares at an exercise price of $17.82, equal to the closing stock price on the grant date. The option has a ten-year term with 25% vesting after one year and subsequent quarterly vesting over three years, contingent on continued service. Fulcrum focuses on rare genetic diseases with lead programs targeting facioscapulohumeral muscular dystrophy and sickle cell disease.

Fulcrum Therapeutics (Nasdaq: FULC) announced that Bryan Stuart, President and CEO, will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 12:00 p.m. ET. A live audio webcast of the presentation will be available on the Investor Relations section of Fulcrum's website, with an archived replay accessible for 30 days following the event.

Fulcrum focuses on addressing rare diseases through innovative treatments like losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease, leveraging its proprietary product engine, FulcrumSeek™.

Fulcrum Therapeutics (NASDAQ: FULC) announced the appointment of Esther Rajavelu as Chief Financial Officer, effective immediately. Rajavelu brings nearly 20 years of experience in the life sciences sector, having held senior positions at UBS, Deutsche Bank, and Bank of America. Fulcrum is focusing on the development of therapies for rare genetic diseases, with promising clinical data for its products losmapimod and FTX-6058.

The company is preparing for significant growth, enhancing its leadership team with Rajavelu's strategic financial expertise.

Fulcrum Therapeutics (NASDAQ: FULC) reported promising results from its Phase 1 trial of FTX-6058, achieving a mean 5.6-fold and 6.2-fold induction of HBG mRNA at 20mg and 30mg doses, respectively, after 14 days. The treatment was well-tolerated, with no serious adverse events noted. New data indicates FTX-6058 effectively downregulates BCL11A and MYB, which are critical repressors of fetal hemoglobin. The company plans to start a Phase 1b trial for sickle cell disease by year-end 2021 and aims to submit an IND for other hemoglobinopathies.

Fulcrum Therapeutics (NASDAQ: FULC) has appointed Sonja L. Banks to its board of directors, effective December 8. Banks, currently the CEO of the International Dyslexia Association, brings 25 years of experience in patient advocacy and non-profit leadership. Her appointment aligns with Fulcrum's mission to advance therapies for rare genetic diseases like sickle cell disease and FSHD. Management believes Banks' expertise will enhance its programs aimed at improving patient outcomes in these areas.

Fulcrum Therapeutics (NASDAQ: FULC) provided a business update and reported Q3 2021 results, highlighting progress in clinical trials. The company is set to initiate a Phase 1b trial for FTX-6058 in sickle cell disease by year-end 2021, with an investigational new drug application expected for other hemoglobinopathies shortly after. Fulcrum raised $144.2 million in August 2021, securing its cash runway into 2024. Collaboration revenue rose to $4.9 million from $1.8 million YoY, while net loss increased to $20.7 million versus $19.0 million YoY. Key updates on losmapimod are anticipated in Q1 2022.